Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 349

1.

Update on the diagnosis and management of gestational trophoblastic disease.

Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:79-85. doi: 10.1002/ijgo.12615.

PMID:
30306586
2.

Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine.

Guevara AM, Suarez E, Victoria A, Ngan HY, Hirschberg AL, Fedrizzi E, Bautista O, Shields C, Joshi A, Luxembourg A.

Hum Vaccin Immunother. 2018 Sep 27:1-5. doi: 10.1080/21645515.2018.1514227. [Epub ahead of print]

PMID:
30261146
3.

Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer.

Liu SS, Chan KKL, Chu DKH, Wei TN, Lau LSK, Ngu SF, Chu MMY, Tse KY, Ip PPC, Ng EKO, Cheung ANY, Ngan HYS.

Mol Oncol. 2018 Sep 17. doi: 10.1002/1878-0261.12383. [Epub ahead of print]

4.

miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Sun J, Cai X, Yung MM, Zhou W, Li J, Zhang Y, Li Z, Liu SS, Cheung ANY, Ngan HYS, Li Y, Dai Z, Kai Y, Tzatsos A, Peng W, Chan DW, Zhu W.

Oncogene. 2018 Aug 30. doi: 10.1038/s41388-018-0459-x. [Epub ahead of print]

PMID:
30166592
5.

Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization.

Wong OGW, Cheung CLY, Ip PPC, Ngan HYS, Cheung ANY.

Am J Pathol. 2018 Oct;188(10):2307-2317. doi: 10.1016/j.ajpath.2018.07.004. Epub 2018 Jul 20.

PMID:
30031727
6.

A Case Series of Five Patients With Pure or Mixed Gestational Epithelioid Trophoblastic Tumors and a Literature Review on Mixed Tumors.

Tse KY, Chiu KWH, Chan KKL, Chu MMY, Ngu SF, Cheung ANY, Ngan HYS, Ip PPC.

Am J Clin Pathol. 2018 Aug 30;150(4):318-332. doi: 10.1093/ajcp/aqy039.

PMID:
29897391
7.

Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface.

Tang MKS, Yue PYK, Ip PP, Huang RL, Lai HC, Cheung ANY, Tse KY, Ngan HYS, Wong AST.

Nat Commun. 2018 Jun 11;9(1):2270. doi: 10.1038/s41467-018-04695-7.

8.

The first pilot study of expanded newborn screening for inborn errors of metabolism and survey of related knowledge and opinions of health care professionals in Hong Kong.

Mak CM, Law EC, Lee HH, Siu WK, Chow KM, Au Yeung SK, Ngan HY, Tse NK, Kwong NS, Chan GC, Lee KW, Chan WP, Wong SF, Tang MH, Kan AS, Hui AP, So PL, Shek CC, Lee RS, Wong KY, Yau EK, Poon KH, Siu S, Poon GW, Kwok AM, Ng JW, Yim VC, Ma GG, Chu CH, Tong TY, Chong YK, Chen SP, Ching CK, Chan AO, Tam S, Lau RL, Ng WF, Lee KC, Chan AY, Lam CW.

Hong Kong Med J. 2018 Jun;24(3):226-237. doi: 10.12809/hkmj176939. Epub 2018 Jun 4.

9.

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.

Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A.

J Infect Dis. 2018 Jun 5;218(1):95-108. doi: 10.1093/infdis/jiy133.

10.

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngan HYS.

Cancer Cell Int. 2018 May 1;18:65. doi: 10.1186/s12935-018-0559-2. eCollection 2018.

11.

DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.

Meng Y, Chen CW, Yung MMH, Sun W, Sun J, Li Z, Li J, Li Z, Zhou W, Liu SS, Cheung ANY, Ngan HYS, Braisted JC, Kai Y, Peng W, Tzatsos A, Li Y, Dai Z, Zheng W, Chan DW, Zhu W.

Cancer Lett. 2018 Aug 1;428:104-116. doi: 10.1016/j.canlet.2018.04.029. Epub 2018 Apr 26.

PMID:
29704517
12.

Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.

Zhou W, Sun W, Yung MMH, Dai S, Cai Y, Chen CW, Meng Y, Lee JB, Braisted JC, Xu Y, Southall NT, Shinn P, Huang X, Song Z, Chen X, Kai Y, Cai X, Li Z, Hao Q, Cheung ANY, Ngan HYS, Liu SS, Barak S, Hao J, Dai Z, Tzatsos A, Peng W, Pei H, Han Z, Chan DW, Zheng W, Zhu W.

Oncogene. 2018 Jul;37(29):3981-3997. doi: 10.1038/s41388-018-0238-8. Epub 2018 Apr 17.

PMID:
29662190
13.

Identification of nonsynonymous TP53 mutations in hydatidiform moles.

Chan KK, Wong ES, Wong OG, Ngan HY, Cheung AN.

Mutat Res. 2018 May;809:20-23. doi: 10.1016/j.mrfmmm.2018.03.006. Epub 2018 Mar 29.

PMID:
29655027
14.

GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.

Yung MM, Tang HW, Cai PC, Leung TH, Ngu SF, Chan KK, Xu D, Yang H, Ngan HY, Chan DW.

Theranostics. 2018 Feb 2;8(5):1270-1285. doi: 10.7150/thno.22536. eCollection 2018.

15.

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.

Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.

Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.

16.

Combined electroacupuncture and auricular acupuncture for postoperative pain after abdominal surgery for gynecological diseases: study protocol for a randomized controlled trial.

Lam WL, Yeung WF, Wong MK, Cheung CW, Chan KKL, Ngan HYS, Wong CKH, Chen HY, Lao L.

Trials. 2018 Jan 4;19(1):8. doi: 10.1186/s13063-017-2359-8.

17.

Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways.

Chen K, Liu MX, Mak CS, Yung MM, Leung TH, Xu D, Ngu SF, Chan KK, Yang H, Ngan HY, Chan DW.

Theranostics. 2018 Jan 1;8(2):423-436. doi: 10.7150/thno.22377. eCollection 2018.

18.

ERBB2 mutation: A promising target in non-squamous cervical cancer.

Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H.

Gynecol Oncol. 2018 Feb;148(2):311-316. doi: 10.1016/j.ygyno.2017.12.023. Epub 2017 Dec 24.

PMID:
29279289
19.

Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.

Leung TH, Tang HW, Siu MK, Chan DW, Chan KK, Cheung AN, Ngan HY.

J Pathol. 2018 Feb;244(2):151-163. doi: 10.1002/path.4991. Epub 2017 Dec 19.

PMID:
28944962
20.

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.

Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang Y, Leung THY, Liu SS, Cheung ANY, Ngan HYS.

BMC Cancer. 2017 Aug 31;17(1):606. doi: 10.1186/s12885-017-3601-1.

21.

Robot-assisted gynaecological cancer surgery-complications and prevention.

Tse KY, Ngan HYS, Lim PC.

Best Pract Res Clin Obstet Gynaecol. 2017 Nov;45:94-106. doi: 10.1016/j.bpobgyn.2017.04.005. Epub 2017 Apr 23. Review.

PMID:
28528932
22.

Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial.

Ngu SF, Wei N, Kwan TTC, Chu MMY, Tse KY, Chan KKL, Ngan HYS.

J Psychosom Obstet Gynaecol. 2018 Jun;39(2):146-155. doi: 10.1080/0167482X.2017.1312335. Epub 2017 Apr 10.

PMID:
28391730
23.

Hidrosadénite suppurée vulvaire : la masse est-elle maligne?

Ngu SF, Chu MMY, Ip PPC, Ngan HYS.

J Obstet Gynaecol Can. 2018 Jan;40(1):2. doi: 10.1016/j.jogc.2017.03.103. Epub 2017 Mar 31. French. No abstract available.

PMID:
28366774
24.

Vulvar Hidradenitis Suppurativa: Is the Mass Malignant?

Ngu SF, Chu MMY, Ip PPC, Ngan HYS.

J Obstet Gynaecol Can. 2018 Jan;40(1):1. doi: 10.1016/j.jogc.2016.10.015. Epub 2017 Mar 31. No abstract available.

PMID:
28366773
25.

MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.

Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, Chan KK, Ngan HY, Chan DW.

Mol Cancer. 2017 Jan 17;16(1):11. doi: 10.1186/s12943-017-0582-2.

26.

The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.

Chow KL, Tse KY, Cheung CL, Wong KW, Cheung AN, Wong RW, Chan AN, Yuen NW, Ngan HY, Ip PP.

Histopathology. 2017 Apr;70(5):746-755. doi: 10.1111/his.13124. Epub 2017 Jan 24.

PMID:
27864989
27.

Successful Treatment of a Pararenal Pregnancy Using High-Dose Methotrexate Regimen: A Case Report.

Tse KY, Cheung VYT, Lam C, Lee EYP, Khong PL, Ngan HYS.

J Reprod Med. 2016 Nov-Dec;61(11-12):592-4.

PMID:
30226730
28.

DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.

Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y, Liang RR, Leung TH, Xu D, Chan KK, Yao KM, Tsang BK, Ngan HY.

Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.

29.

Patient compliance with cervical smear surveillance in a shared-care setting.

Tse KY, Lau SK, Lui MW, Ip PP, Cheung AN, Ngan HY.

Int J Gynaecol Obstet. 2016 Nov;135(2):177-181. doi: 10.1016/j.ijgo.2016.04.012. Epub 2016 Jul 7.

PMID:
27451399
30.

Extremely stringent activation of p16INK4a prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression.

Hang S, Tiwari AF, Ngan HY, Yip YL, Cheung AL, Tsao SW, Deng W.

Oncotarget. 2016 Jul 19;7(29):45656-45670. doi: 10.18632/oncotarget.10120.

31.

Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline.

Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, Gupta V, Horton S, Jacob G, Kidd EA, Lishimpi K, Nakisige C, Nam JH, Ngan HYS, Small W, Thomas G, Berek JS.

J Glob Oncol. 2016 May 25;2(5):311-340. doi: 10.1200/JGO.2016.003954. eCollection 2016 Oct.

32.

Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.

Yung MM, Ngan HY, Chan DW.

Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):301-17. doi: 10.1093/abbs/gmv128. Epub 2016 Jan 12. Review.

33.

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.

Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A.

Int J Gynecol Cancer. 2018 Jan;28(1):2-10. doi: 10.1097/IGC.0000000000000602.

PMID:
26588236
34.

Chemotherapy in pregnancy.

Ngu SF, Ngan HY.

Best Pract Res Clin Obstet Gynaecol. 2016 May;33:86-101. doi: 10.1016/j.bpobgyn.2015.10.007. Epub 2015 Oct 19. Review.

PMID:
26553395
35.

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.

Yung MM, Ross FA, Hardie DG, Leung TH, Zhan J, Ngan HY, Chan DW.

Integr Cancer Ther. 2016 Sep;15(3):376-89. doi: 10.1177/1534735415611747. Epub 2015 Oct 19.

36.

Update on the diagnosis and management of gestational trophoblastic disease.

Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR.

Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S123-6. doi: 10.1016/j.ijgo.2015.06.008. No abstract available.

37.

The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.

Chu MM, Liu SS, Tam KF, Ip PP, Cheung AN, Ngan HY.

Int J Gynecol Pathol. 2015 Sep;34(5):403-10. doi: 10.1097/PGP.0000000000000174.

PMID:
26262451
38.

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.

Siu MK, Kong DS, Ngai SY, Chan HY, Jiang L, Wong ES, Liu SS, Chan KK, Ngan HY, Cheung AN.

PLoS One. 2015 Jul 28;10(7):e0133467. doi: 10.1371/journal.pone.0133467. eCollection 2015.

39.

FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling.

Mak VC, Wong OG, Siu MK, Wong ES, Ng WY, Wong RW, Chan KK, Ngan HY, Cheung AN.

Am J Pathol. 2015 Jul;185(7):2038-48. doi: 10.1016/j.ajpath.2015.03.011.

PMID:
26093985
40.

The role of laparoscopy in staging of different gynaecological cancers.

Tse KY, Ngan HY.

Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):884-95. doi: 10.1016/j.bpobgyn.2015.01.007. Epub 2015 Mar 4. Review.

PMID:
25819676
41.

HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis.

Leung TW, Liu SS, Leung RC, Chu MM, Cheung AN, Ngan HY.

J Med Virol. 2015 Jun;87(6):1022-33. doi: 10.1002/jmv.24129. Epub 2015 Feb 3.

PMID:
25648229
42.

Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.

Chu MM, Ma Y, Tse KY, Chan KK, Ngan HY.

Int J Gynecol Cancer. 2015 Mar;25(3):498-503. doi: 10.1097/IGC.0000000000000383.

PMID:
25628108
43.

Asian Society of Gynecologic Oncology International Workshop 2014.

Park JY, Ngan HY, Park W, Cao Z, Wu X, Ju W, Chung HH, Chang SJ, Park SY, Ryu SY, Kim JH, Cho CH, Lee KH, Lee JW, Kumarasamy S, Kim JW, Wilailak S, Kim BG, Kim DY, Konishi I, Lee JK, Wang KL, Nam JH.

J Gynecol Oncol. 2015 Jan;26(1):68-74. doi: 10.3802/jgo.2015.26.1.68.

44.

Integrated human papillomavirus analysis as an adjunct for triage of atypical cervical cytology.

Cheung AN, Wong OG, Chan KK, Yang MS, Tsang CH, Ji SL, Lo CK, Szeto E, Wong E, Ngan HY.

Hong Kong Med J. 2014 Dec;20 Suppl 6:44-7. No abstract available.

45.

Cervical cancer screening by enhanced cytology: application of novel markers.

Cheung AN, Guan XY, Ngan HY.

Hong Kong Med J. 2014 Dec;20 Suppl 6:39-43. No abstract available.

46.

Human papillomavirus status in southern Chinese women.

Liu SS, Chan KK, Leung RC, Yip AM, Lau LS, Liao XY, Jiang LL, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY.

Hong Kong Med J. 2014 Dec;20 Suppl 6:35-8. No abstract available.

47.

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, Khongkow P, Lam EW, Cheung AN.

PLoS One. 2014 Nov 20;9(11):e113478. doi: 10.1371/journal.pone.0113478. eCollection 2014.

48.

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S109-16. doi: 10.1097/IGC.0000000000000294. Review.

PMID:
25341573
49.

Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling.

Cai PC, Shi L, Liu VW, Tang HW, Liu IJ, Leung TH, Chan KK, Yam JW, Yao KM, Ngan HY, Chan DW.

Oncotarget. 2014 Sep 15;5(17):7549-62.

50.

Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer.

Chan KK, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK, Ngan HY.

J Endocrinol. 2014 May 12;221(2):325-36. doi: 10.1530/JOE-13-0500. Print 2014 May.

PMID:
24819599

Supplemental Content

Support Center